# Fella Health **Source:** https://geo.sig.ai/brands/fella-health **Vertical:** Healthcare **Subcategory:** General **Tier:** Challenger **Website:** fellahealth.com **Last Updated:** 2026-04-14 ## Summary SF YC W20/S21 men's GLP-1 obesity telemedicine at $50M+ ARR cashflow positive 24 months with $130K total raised; competing with Ro and Hims for men's obesity treatment at massive capital efficiency targeting 1M patients by end 2026. ## Company Overview Fella Health is a San Francisco-based men's obesity telemedicine platform — bootstrapped with minimal external funding ($130,000 seed from Y Combinator, Global Founders Capital, AngelList, and founders of Indeed, Curative, and Alan) — providing men with obesity and metabolic health challenges with a subscription-based direct-to-patient treatment program combining FDA-approved GLP-1 medications (semaglutide and tirzepatide), psychological strengthening, and behavioral interventions for significant weight loss and metabolic health improvement. Having achieved over $50 million in annual recurring revenue and cashflow positive operations for 24 months, with 76+ employees and a mission to serve 1 million men by end of 2026, Fella also operates Delilah Health for women through the same clinical model. Y Combinator W20/S21 backed. Fella Health's men's obesity telemedicine model capitalizes on the GLP-1 medication revolution in obesity treatment while adding the behavioral support that clinical evidence shows improves long-term outcomes: semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) achieve 15-22% body weight reduction in clinical trials — but the drugs are expensive ($1,000-$1,300/month list price), require physician oversight, and work best when combined with lifestyle modification that sustains the metabolic changes after medication titration. Fella's subscription model (typically $150-300/month, far below GLP-1 medication list price) achieves the medication access and behavioral support combination by sourcing compounded semaglutide through FDA-registered compounding pharmacies during the branded GLP-1 supply shortage, providing physician prescribing through synchronous and asynchronous telemedicine consultations, and delivering the health coaching that supports sustainable behavior change alongside the medication. In 2025, Fella Health competes in the men's health telemedicine, GLP-1 obesity treatment, and direct-to-consumer metabolic health market with Ro (men's health telehealth, $876M raised at $5B valuation), Calibrate (metabolic health program, $100M raised), and Hims & Hers (NYSE: HIMS, men's and women's telehealth, $526M revenue 2024) for men with obesity and metabolic health telemedicine program adoption. The $50M+ ARR with $130K in external funding represents one of the most capital-efficient telehealth companies in the GLP-1 obesity treatment market. The cashflow positive milestone (24 months) demonstrates the business model sustainability that VC-heavy telehealth competitors have not yet achieved. The 2025 strategy focuses on the expansion to Fella's 1 million patient milestone, building the metabolic health monitoring platform for longitudinal GLP-1 treatment outcomes tracking, and growing the Delilah women's health brand as a parallel market opportunity. ## Frequently Asked Questions ### What is Fella Health? Fella Health is a telemedicine clinic founded in 2020 that specializes in treating obesity in men. The company combines FDA-approved GLP-1 medications, psychological strengthening, and behavioral interventions to improve metabolic health and drive significant weight loss. ### What products and services does Fella Health offer? Fella Health offers a subscription-based obesity treatment program that includes men's weight loss telehealth, FDA-approved GLP-1 medications (Semaglutide and Tirzepatide), behavioral coaching, and psychological support. The program is delivered through a direct-to-patient model. ### Who is Fella Health designed for? Fella Health is specifically designed for men with obesity who are seeking weight loss and metabolic health improvements. The company's goal is to serve 1 million men by the end of 2026. ### When was Fella Health founded? Fella Health was founded in 2020 and participated in Y Combinator's Winter 2020 (W20) batch. ### Where is Fella Health located? Fella Health is based in San Francisco, California. ### How much funding has Fella Health raised? Fella Health raised minimal external funding of $130K in seed funding from Y Combinator, Global Founders Capital, AngelList Quant Fund, and founders of Indeed, Curative, Alan, Kaia Health, Vouch Insurance, and Not Boring. The company has since bootstrapped its growth to over $50M ARR. ### What are Fella Health's key achievements and metrics? Fella Health has achieved over $50M in annual recurring revenue (ARR) and has been cashflow positive for 24 months. The company operates with 76 employees, generates $11.6M-$14.7M in revenue, and aims to serve 1 million customers by the end of 2026. ### What is Fella Health's treatment approach? Fella Health uses a comprehensive approach that combines FDA-approved GLP-1 medications (Semaglutide and Tirzepatide) with psychological strengthening and behavioral interventions. This multi-faceted approach targets both the medical and behavioral aspects of obesity treatment. ### What type of medications does Fella Health prescribe? Fella Health prescribes FDA-approved GLP-1 medications, specifically Semaglutide and Tirzepatide, as part of its obesity treatment program. These medications are combined with coaching and psychological support for comprehensive care. ### What are Fella Health's recent developments? As of 2025, Fella Health has surpassed $50M in ARR while maintaining cashflow positive status for 24 months. The company continues to operate with minimal external funding and has set an ambitious goal to reach 1 million customers by the end of 2026. ## Tags healthtech, global, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*